Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform

Eli Lilly invests $1.1 billion in METiS TechBio's AI drug delivery platform.

Eli Lilly has made a significant investment in METiS TechBio, a Hong Kong-based biotech company.

METiS TechBio's AiLNP platform utilizes machine learning models to develop lipid nanoparticles.

The platform aims to improve tissue specificity, potentially enhancing a drug's therapeutic performance.